Skip to content

New drug used to treat breast cancer heralded as 'quite groundbreaking'

By Catholic Online (NEWS CONSORTIUM)
4/6/2014 (3 years ago)
Catholic Online (www.catholic.org)

Drug cut in half the risk that cancer would worsen

An important treatment option in the fight against breast cancer may be waiting in the wings. Researchers say a new type of drug could help prevent advanced breast cancer from worsening. The potential is great for breast cancer patients, and makes for a potential blockbuster product for Pfizer.

While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor.

While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor.

Highlights

By Catholic Online (NEWS CONSORTIUM)
Catholic Online (www.catholic.org)
4/6/2014 (3 years ago)

Published in Health

Keywords: Pfizer, breast cancer, palbociclib


LOS ANGELES, CA (Catholic Online) - Said drug cut in half the risk that cancer would worsen, or progress, researchers said. The median time before the disease progressed or the women died was 20.2 months for those who received the drug, compared with 10.2 months for the control group.

"The magnitude of benefit we are seeing is not something commonly seen in cancer medicine studies," Dr. Richard S. Finn, a principal investigator in the study, says. Finn, an oncologist at the University of California, Los Angeles, called the results "quite groundbreaking."

No child need ever go to bed hungry -- Learn how you can help!

Known as palbociclib, the drug also appeared to prolong survival but not by a statistically significant amount. Those who received the drug lived a median of 37.5 months in contrast with 33.3 months for those in the control group.

The results from the Phase 2, or mid-stage, study were presented here at the annual meeting of the American Association for Cancer Research. Palbociclib is considered a jewel in Pfizer's product pipeline, with analysts predicting annual sales of billions of dollars. Amgen is entitled to an eight percent royalty on sales of the drug.

Some investors may have been letdown due to the drug, partly because they were not quite as good as interim results presented about halfway through the trial. At that point, the difference in median progression-free survival was 26.1 months for palbociclib versus 7.5 months for the control group.

Finn stresses that a statistically significant survival benefit should not have been expected at this point because only 61 of the 165 patients in the trial had died. Patients can use other drugs after leaving the trial, which can dilute any effect of palbociclib.

Palbociclib slows the proliferation of cancer cells by inhibiting the activity of two related enzymes involved in cell division; cyclin-dependent kinases 4 and 6.

While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor. While breast cancer is the initial focus, the drugs are being tested for other cancers.

Breast cancer specialists not involved in the study were encouraged -- but expressed caution. "These results are strikingly positive and with a large potential impact to patients," Dr. José Baselga said in a speech at the conference discussing the results.

Baselga, the physician in chief at the Memorial Sloan-Kettering Cancer Center, also said the results might have been biased because the study investigators, who determined whether tumors had progressed, knew which patients were getting palbociclib.

Dr. Eric P. Winer, chief of women's cancers at the Dana-Farber Cancer Institute in Boston, says larger studies were still needed.

"This is a small Phase 2 trial - not tiny, but not the kind of study that would typically lead to a change in practice," he said.

---


'Help give every student and teacher Free resources for a world-class moral Catholic education'


Copyright 2017 - Distributed by THE CALIFORNIA NETWORK

Pope Francis Prayer Intentions for OCTOBER 2017
Workers and the Unemployed.
That all workers may receive respect and protection of their rights, and that the unemployed may receive the opportunity to contribute to the common good.


Comments


More Health

Australian Dr. Death invents 3D printable suicide machine Watch

Image of The suicide machine is impractical and ridiculous but is being used to spark conversation about euthanasia.

An Australian man whose friends call him 'Dr. Death,' has invented a 3D printable suicide machine. LOS ANGELES, CA (California Network) - ... continue reading


What does it feel like to die? Evidence suggests a surprising answer Watch

Image of According to the evidence, death isn't something to be feared.

What does it feel like to die? This is a question that everyone has, but few people can answer. Now, a growing body of scientific and ... continue reading


Here's the best scientific argument yet against pornography Watch

Image of Pornography addiction is destroying lives, and the science proves it.

In 2013, Beyonce Knowles topped GQ's list of "The 100 Hottest Women of the 21st Century." San Francisco, CA (CNA/EWTN News) - That same ... continue reading


Aspirin may help people avoid some form of cancer Watch

Image of Does an aspirin a day keep cancer away? It does according to one study.

Aspirin may help people avoid many cancers, according to a study of 600,000 people performed in China. LOS ANGELES, CA (California Network) ... continue reading


The next global outbreak has arrived. Plague is spreading across Africa and is one flight away from going global as experts warn 'something is different' Watch

Image of Health officials have blamed ceremonies that involve digging up the dead and reburying them for the current outbreak, but this has not been confirmed. Still, they have asked people to halt the practice.

Millions of people around the world, including you, are in danger, but few people know it. However, experts from the World Health ... continue reading


Never Miss any Updates!

Stay up to date with the latest news, information, and special offers.

Information
Learn about Catholic world

Catholic Online
Inform - Inspire - Ignite

Catholic Online Saints
Your saints explained

Catholic Online Prayers
Prayers for every need

Catholic Online Bible
Complete bible online

Catholic Online News
Your news Catholic eye

Daily Reading
Today's bible reading

Lent / Easter
Death & resurrection of Jesus

Advent / Christmas
Birth of Jesus

Rest of Catholic Online
All Catholic world we offer

Services
Products and services we offer

Catholic Online Shopping
Catholic medals, gifts & books

The California Network
Inspiring streaming service

Advertise on Catholic Online
Your ads on catholic.org

Catholic Online Email
Email with Catholic feel

Catholic Online Singles
Safe, secure Catholic dating

The California Studios
World-class post production service

Education
Learn the Catholic way

Catholic Online School
Free Catholic education for all

Student Classes
K-12 & Adult Education Classes

Catholic Online MasterClass
Learn from experts

School Teachers
Teacher lesson plans & resources

Catholic Media Missionaries
The New Evangelization

Support Free Education
Tax deductible support Free education

Socials
Connect with us online

Catholic Online on Facebook
Catholic social network

Catholic Online on Twitter
Catholic Tweets

Catholic Online on YouTube
Enjoy our videos

Catholic Online on Instagram
Shared Catholic moments

Catholic Online on Pinterest
Catholic ideas style inspiration

Catholic Online Logo

Copyright 2017 Catholic Online. All materials contained on this site, whether written, audible or visual are the exclusive property of Catholic Online and are protected under U.S. and International copyright laws, © Copyright 2017 Catholic Online. Any unauthorized use, without prior written consent of Catholic Online is strictly forbidden and prohibited.